BioMed Research International / 2013 / Article / Tab 1

Review Article

The Treatment Outcome and Radiation-Induced Toxicity for Patients with Head and Neck Carcinoma in the IMRT Era: A Systematic Review with Dosimetric and Clinical Parameters

Table 1

Published studies with either IMRT or conventional techniques. Data included primary site, stage, intention of RT, concomitant chemotherapy or not, followup, and treatment outcome.

Study No. of patients Primary
tumor site
TN stage RT Intention for RT Concurrent
chemotherapy
Median followup
(Range)
Treatment outcome %
Regional
control  
(RC)
Local
control  
(LC)
Locoregional control (LRC) Distant metastases-free
survival (DMFS)
Disease-free
survival
(DFS)
Overall
survival  
(OS)
no. of
pts  (%)
no. of
pts  (%)

Studer et al. [24]29Hypopharynx T1–T4
N0–N3
IMRT Def: 90%
Post: 10%
YES (86%) 16 mths (4–44 mths) 93% (2yrs) 90% (2yrs)93% (2yrs)90% (2yrs)

Lee et al. [8]41OropharynxT1–T4
N0–N3
St: III–IVB
IMRT DefYes31 mths (20–64 mths)94% (3yrs)95% (3yrs) 92% (3yrs)86% (3yrs)82% (3yrs)91% (3yrs)
71OropharynxT1–T4
N0–N3
St: III–IVB
2DRT DefYes 46 mths (3–93 mths)95% (3yrs) 85% (3yrs)82% (3yrs)85% (3yrs)76% (3yrs)81% (3yrs)

Garden et al. [25]51OropharynxTx, T1-T2
Nx, N0–N3
IMRTDefYes (8%)45 mths (15–63 mths)96% (2yrs)93% (2yrs)87% (2yrs)93% (2yrs)

Daly et al. [26]107OropharynxT1–T4
N0–N3
St: II–IV
IMRTDef: 80%
Post: 20%
Yes (87%)29 mths (4–105 mths) 92% (3yrs) 92% (3yrs) 81% (3yrs)83% (3yrs)

Chao et al. [27]74OropharynxT1–T4
N0–N3
St: I–IV
IMRTDef: 42%
Post: 58%
Yes (23%)33 mths (9–60 mths)87% (3yrs) 90% (4yrs) 81% (4yrs) 87% (4yrs)

Huang et al. [28]71OropharynxT1–T4
N0–N3
St: III-IV
IMRTDefYes33 mths (3–72 mths)94% (3yrs) 94% (3yrs)90% (3yrs)83% (3yrs)

Setton et al. [29]442OropharynxT1–T4
N0–N3
St: I–IV
IMRTDef: 93%
Post: 7%
Yes (88%)36.8 mths (3–135 mths)94.4% (3yrs)94.6% (3yrs)87.5% (3yrs)84.9% (3yrs)

Schoenfeld et al. [30]64OropharynxT1–T4
N0–N3
St: I–IVB
IMRTDefYes (54%)36 mths (12–62 mths)94% (3yrs)90% (3yrs)RFS: 86%
(3yrs)
84% (3yrs)

Clavel et al. [9]100OropharynxT1–T4
N0–N3
St: III–IVB
IMRT DefYes42 mths95.1% (3yrs)85.3% (3yrs)92.1% (3yrs)
149OropharynxT1–T4
N0–N3
St: III–IVB
2-3DRT DefYES42 mths84.4% (3yrs)69.3% (3yrs)75.2% (3yrs)

Sanguineti et al. [31]50OropharynxTx, T1–T4
N0–N3
IMRTDefNo32.6 mths
(12.1–58.6 mths)
85% (3yrs)94% (3yrs)

De Arruda et al. [32]50OropharynxT1–T4
N0–N3
St: I–IV
IMRTDef: 96%
Post: 4%
Yes (86%)18 mths (8.4–76 mths)88% (2yrs)98% (2yrs)84% (2yrs)98% (2yrs)

Fang et al. [10]113NasopharynxT1–T4
N0–N3
St: I–IV
IMRTDefYes (57.3%)40 mths (5–57 mths)84% (3yrs)83% (3yrs) 85% (3yrs)
93NasopharynxT1–T4
N0–N3
St: I–IV
3D-CRTDefYes (54.8%)46 mths (10–59 mths)84.8% (3yrs)76.7% (3yrs) 81.7% (3yrs)

Wong et al. [33]175NasopharynxT1–T4
N0–N3
St: I–IVB
IMRTDefYes (70%)34 mths (9–50 mths)93.3% (3yrs) 93.6% (3yrs)86.6% (3yrs)87.2% (3yrs)

Kwong et al. [34]33Nasopharynx T1–T3
N0-N1
IMRTDefNo 24 mths (11–42 mths) 93% (3yrs) 100% (3yrs)100% (3yrs) 100% (3yrs)

Wolden et al. [35]74NasopharynxT1–T4
N0–N3
St: I–IVB
IMRTDefYes (93%)35 mths (3–74 mths) 93%
(3yrs)
91%
(3yrs)
78% (3yrs) 67% (3yrs)83% (3yrs)

Kam et al. [36]63NasopharynxT1–T4
N0–N3
St: I–IV
IMRTDefYes (30%)29 mths (8–45 mths)98% (3yrs)92% (3yrs)79% (3yrs) 90% (3yrs)

Tham et al. [37]107NasopharynxT1–T2
N0–N1
St: IIB
IMRTDefYes (7%)39 mths (7–77 mths)98% (3yrs)96.5% (3yrs)94.8% (3yrs)90.7% (3yrs)95.8% (3yrs)

Lee et al. [38]68NasopharynxT1–T4
N0–N3
St: I–IVB
IMRTDefYes (65%)31 mths (6–55 mths)90.8% (2yrs)92.6% (2yrs) 89.3% (2yrs)84.7% (2yrs) 72.7% (2yrs)80.2% (2yrs)

Tham et al. [39]195NasopharynxT1–T4
N0–N3
St: I–IVB
IMRTDefYes (57%)36.5 mths89.6% (3yrs)89.2% (3yrs)79% (3yrs)94.3% (3yrs)

Lee et al. [40]67NasopharynxT1–T4
N0–N3
St: I–IV
IMRTDefYes (75%)31 mths (7–72 mths)98% (4yrs) 97% (4yrs)66% (4yrs)88% (4yrs)

Liu et al. [41]19NasopharynxT1–T4
N0–N3
St: I–IV
IMRTDefYes (58%)13.0 mths (8–18 mths)100%
(13 mths)

Luo et al. [42]58NasopharynxT1–T4
N0–N3
St: I-II
3D-CRTDefNo58 mths (25–92 mths) 93% (5yrs)98% (5yrs) 91% (5yrs) 95% (5yrs)

Wang et al. [43]300NasopharynxT1–T4
N0–N3
St: IIB
IMRTDefYes (83%)47.1 mths (11–68 mths)95.1% (4yrs)94% (4yrs)85% (4yrs)86.1% (4yrs)

Sultanem et al. [44]35NasopharynxT1–T4
N0–N3
St: I–IVB
IMRTDefYes (91%)21.8 mths (5–49 mths)100% (4yrs)57% (4yrs)57% (4yrs)94% (4yrs)

Su et al. [45]198NasopharynxT1-T2
N0-N1
St: I–IIB
IMRTDefNo50.9 mths (12–104 mths)97.7% (5yrs)97.8% (5yrs)97.3% (5yrs)

Kim et al. [46]21NasopharynxT2–T4
N0–N2
St: III-IV
3D-CRTDefNo48 mths85% (5yrs) 61% (5yrs)

Al-Mamgani et al. [47]170LarynxT3
N0–N3
IMRT +
3D-CRT
DefYes (28.3%)32 mths (7–172 mths)73% (3yrs)70% (3yrs) 64% (3yrs)61% (3yrs)

Studer et al. [48] 58Oral cavityDef T2–T4
N0–N3
St: IVA-B
Post T1–T4
N0–N2c
St: II–IVA
IMRTDef: 52%
Post: 48%
Yes (78%)Def: 19 mths
Post: 12 mths
Def: 43%
(2yrs)
Post: 92%
(2yrs)
Def: 40%
(2yrs)
Post: 87%
(2yrs)
Def: 30%
(2yrs)
Post: 83%
(2yrs)

Chen et al. [21]22Oral cavity T1–T4
N0–N2c
St: III-IV
IMRTPostYes (9%)44 mths64% (3yrs)67% (3yrs)
27Oral cavityT1–T4
N0–N2c
St: III-IV
3D-CRTPostYes (2%)44 mths66% (3yrs)77% (3yrs)

Yao et al. [49] 55Oral cavityTx–T4
N0–N2c
St: I–IV
IMRTDef: 9%
Post: 91%
Yes
Def: 6%
Post: 4%
23.9 mths (9.3–59.3 mths)85% (3yrs)82% (3yrs)89% (3yrs)74% (3yrs)*68% (3yrs)

Lee et al. [50]31VariousT1–T4
N0–N2
St: I–IVB
IMRTDefYes (65%)26 mths (17–58 mths)86% (2yrs)94% (2yrs)92% (2yrs) 63% (2yrs)

Van Gestel et al. [51]78VariousTx, T1–T4
Nx, N0–N3
St: I–IVB
IMRTDef: 62%
Post: 38%
Yes
Def: 63%
Post: 23%
18.7 mths (0.13–51.7 mths)Def: 66.8% (3yrs)
Post: 82.2% (3yrs)
Def: 42.6%
(3yrs)
Post: 82.2%
(3yrs)
Def: 60.3%
(3yrs)
Post: 85.9%
(3yrs)

Peponi et al. [52]82Various St: I–IVIMRTDef: 77%
Post: 23%
Yes (85%)55 mths78% (3yrs) 80% (3yrs)

Gupta et al. [23]28VariousT1–T3
N0–N2b
St: I–IV
3D-CRTDefYes40 mths (26–50 mths)88.2% (3yrs)70.6% (3yrs)
32VariousT1–T3
N0–N2b
St: I–IV
IMRTDefYes (90%)40 mths (26–50 mths)88.2% (3yrs)68% (3yrs)

Lambrecht et al. [18]135VariousT1–T4
N0–N3
St: III-IV
3D-CRTDefYes (80%)68 mths (37.2–104 mths)71% (3yrs)61% (3yrs)
110VariousT1–T4
N0–N3
St: III-IV
IMRTDefYes (81%)35 mths (4.7–63.5 mths)70% (3yrs) 64% (3yrs)

Toledano et al. [53]208VariousSt: I–IVIMRTDef: 55%
Post: 45%
Yes (37.5%)25.3 mths (0.4–72 mths)86% (2yrs) 92.7% (2yrs)80% (2yrs)86.7% (2yrs)

Rades et al. [22]104VariousT0–T4
N0–N3
St: I–IV
2DRT PostYes (8%)78% (2yrs)79% (2yrs)74% (2yrs)
26VariousT0–T4
N0–N3
St: I–IV
3D-CRTPostYes (23%)79% (2yrs)83% (2yrs)80% (2yrs)
18VariousT0–T4
N0–N3
St: I–IV
IMRTPostYes (6%)89% (2yrs)80% (2yrs)86% (2yrs)

Yao et al. [54]150VariousT0–T4
N0–N3
St: I–IV
IMRTDef: 66%
Post: 34%
Yes (45%)18 mths (2–60 mths)94% (2yrs)92% (2yrs)87% (2yrs)85% (2yrs)

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.